Home › Broca Aphasia › NCT01818661
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
RecruitingPhase 4
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic Exclusion Criteria: * Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded. * Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan. * Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy). * Subjects will also be excluded if they do not have an informant, or do not consent to research.
About the study
The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).
What is being tested
- AV-1451 (drug)
Sponsor: Mayo Clinic · Participants: 50 · Started: Jul 1, 2018
Contact the study team
- Sarah Boland, CCRP · Phone: 507-284-3863
Official record on ClinicalTrials.gov — NCT01818661
Locations in the U.S.
| Minnesota | Mayo Clinic, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.